文献速递皮肤肿瘤

BRAF/MEK抑制剂联合再挑战治疗转移性BRAF V600突变黑色素瘤成功案例

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-05-08

本文报告两例转移性BRAF V600突变黑色素瘤患者,在靶向治疗进展并后续接受抗CTLA-4和抗PD-1免疫治疗后,再次使用BRAF和MEK抑制剂联合治疗。两例患者均对再治疗有应答,应答持续数月,并与生活质量显著提高相关。结论认为,当激酶抑制剂和免疫治疗均进展且其他选择耗尽时,再挑战BRAF/MEK抑制剂联合治疗可作为一种可行选择。

要点

  • 两例BRAF V600突变转移性黑色素瘤患者靶向及免疫治疗后进展,再挑战BRAF/MEK联合治疗均获应答。
  • 再治疗应答仅持续数月,但伴随生活质量显著提高。
  • 所有其他治疗选择耗尽时,可考虑BRAF/MEK抑制剂联合再挑战。

核心结论

  • BRAF和MEK抑制剂联合再挑战可能是激酶抑制剂和免疫治疗均进展后的一种可行治疗选择,应在所有其他治疗选择耗尽时考虑。

研究设计与样本

  • 本文为病例报告,纳入两例转移性BRAF V600突变黑色素瘤患者。
  • 两例患者均在靶向治疗进展后接受抗CTLA-4和抗PD-1抗体免疫治疗,随后再挑战BRAF和MEK抑制剂联合治疗。

主要发现

  • 两例患者均对再挑战治疗有应答。
  • 应答持续仅数月,并与生活质量显著提高相关。

临床怎么用

  • 当转移性BRAF V600突变黑色素瘤患者经激酶抑制剂和免疫治疗均进展且其他选择耗尽时,可考虑BRAF/MEK抑制剂联合再挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination treatment with BRAF and MEK inhibitors is amongst the current standard of care for stage IIIC/IV BRAF-mutated melanoma. However, therapeutic options are limited once patients have progressed upon both targeted and immunotherapy. OBJECTIVE: To investigate whether retreatment with BRAF and MEK inhibitor combination is an option for patients with metastatic BRAF-mutated melanoma upon previous progression on kinase inhibitors. METHODS: Two patients with metastatic BRAF-mutated melanoma were rechallenged with BRAF and MEK inhibitor combination after progression on targeted therapy and subsequent immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies. RESULTS: Both patients responded to retreatment. Responses were limited to a few months and associated with a considerable increase in quality of life. CONCLUSION: Retreatment with BRAF and MEK inhibitors may present a feasible treatment option upon progression on both kinase inhibitors and immunotherapy, and should be considered when all other treatment options have been exhausted.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Amann VC, Hoffmann D, Mangana J, et al. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. J Eur Acad Dermatol Venereol. 2017. PMID: 28401596. doi:10.1111/jdv.14268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。